Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803227 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
A Phase 1 study, sponsored by Histogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04803227 is a Phase 1 study that was terminated before completion, run by Histogen. The registered enrollment target is 13 participants.
The verdict
NCT04803227, a Phase 1 study, was terminated before completion, sponsored by Histogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
Treatments for COVID-19 are urgently needed. Emricasan (EMR) is a pan caspase inhibitor. Caspase-1 plays a role in a form of cell death called pyroptosis. EMR inhibits pyroptosis. The Investigators have shown that peripheral blood lymphocytes of COVID-19 patients overexpress caspase-1, providing evidence for pyroptosis. A recent European study corroborate the Investigators finding as they have shown evidence for the activation of the inflammasome in COVID-19.
Interventions
- OTHER Placebo
- DRUG Emricasan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-03-11 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04803227
The ClinicalTrials.gov registry entry for NCT04803227 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Histogen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04803227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04803227 about?
NCT04803227 is a clinical study titled "Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19". Treatments for COVID-19 are urgently needed. Emricasan (EMR) is a pan caspase inhibitor. Caspase-1 plays a role in a form of cell death called pyroptosis. EMR inhibits pyroptosis. The Investigators have shown that peripheral blood lymphocytes of COVID-19 patients overexpress caspase-1, providing evi...
What is the current status of trial NCT04803227?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-03-11. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT04803227?
The interventions under investigation include: Placebo (OTHER), Emricasan (DRUG).
Who is sponsoring clinical trial NCT04803227?
This trial is sponsored by Histogen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.